KalVista (KALV) CEO Sells $193,065 in Company Stock
Published on 4/20/2026
AI Summary
Summarized by AI from the source belowKalVista Pharmaceuticals' CEO, Benjamin Palleiko, sold $193,065 worth of company stock. This transaction may raise concerns among investors regarding the CEO's confidence in the company's future prospects. The stock sale's timing and implications for shareholder value can affect market perceptions. Monitoring such insider transactions can provide insights into future price movements for KalVista (KALV).
Get the free market brief
Top stories and analysis, summarized. No spam, unsubscribe anytime.
